EGFR and cancer: To date, the bulk of evidence suggests that targeting a single oncogenic target or pathway would most likely be insufficient to achieve meaningful clinical responses and long-term survival of patients with most cancer types, despite a few exceptions (e.g., BCR/ABL inhibitors in CML and EGFR or ALK inhibitors in NSCLC).